A new coumamin anticoagulant, acenocoumarin (Sintrom) is compared with other hypoprothromwbinemic agents in the same human subjects. Comparing doses which result in the same peak prothrombin time, both speed of onset and duration of effect are found to be a function of the rate of biotransformation. Rapid biotransformation results in fast onset and short duration of action and vice versa. Sintrom is intermediate between the slow, long-acting compounds (Dicumarol, Warfarin, Coumopyrin) and the fast, short-acting Tromexan. One 16 to 32 mg. dose of Sintrom rapidly results in a desirable hypoprothrombinemia which is maintained by a single daily dose of 2 to 10 mg.
In order to compare the speed of onset and duration of effect of various hypoprothrombinemic agents in man, it is necessary to determine what single dose of each compound, tested in the same subject, would give the same peak prothrombin response. In our studies, a prothrombin time of 23 seconds* (equivalent to 50 seconds in 12.5 per cent saline-diluted plasma) was chosen as the peak prothrombin effect to be sought in each subject with single doses of each drug. The prothrombin response to various single doses of eight different hypoprothrombinemic agents was studied in each of five subjects. In each instance, at least one week was allowed to elapse between recovery from the previous dose and administration of the next dose. The dose necessary to achieve a peak prothrombin response of 23 seconds (control 13.5 seconds) was thus determined for each drug in each subject. The average dose necessary for this response and the average pattern of the response are summarized in 
